Daniel Petrylak
丹尼尔·彼得里亚克
MD
Professor of Medicine and Urology, Co-Director of GU Oncology Program内科及泌尿外科教授、泌尿生殖肿瘤项目联合主任
👥Biography 个人简介
Daniel Petrylak is a Yale bladder and prostate cancer specialist renowned for pioneering work on antibody-drug conjugates including sacituzumab govitecan and docetaxel-based regimens. His decades of GU oncology research have generated multiple FDA-approved therapies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Antibody-Drug Conjugates in Bladder Cancer
Led TROPHY-U-01 trial evaluating sacituzumab govitecan in platinum-refractory metastatic urothelial carcinoma, contributing to its FDA approval for this indication.
Docetaxel in Prostate Cancer
Co-led the pivotal SWOG 9916 trial demonstrating docetaxel plus estramustine improved survival in metastatic castration-resistant prostate cancer versus mitoxantrone.
Representative Works 代表性著作
Sacituzumab Govitecan in Metastatic Urothelial Carcinoma
Journal of Clinical Oncology (2021)
TROPHY-U-01 cohort 1 results supporting FDA approval of sacituzumab govitecan in urothelial carcinoma.
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Prostate Cancer
New England Journal of Medicine (2004)
SWOG 9916 trial demonstrating survival benefit of docetaxel in metastatic CRPC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Jonathan Rosenberg
Memorial Sloan Kettering Cancer Center
Matthew Galsky
Icahn School of Medicine at Mount Sinai
Andrea Apolo
National Cancer Institute, NIH
Sumanta Pal
City of Hope Comprehensive Cancer Center
关注 丹尼尔·彼得里亚克 的研究动态
Follow Daniel Petrylak's research updates
留下邮箱，当我们发布与 Daniel Petrylak（Yale School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment